Legend Accounts Payable vs Net Receivables Analysis

LEGN Stock

USD 42.39 0.74 1.72%

Legend Biotech financial indicator trend analysis is infinitely more than just investigating Legend Biotech Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Legend Biotech Corp is a good investment. Please check the relationship between Legend Biotech Accounts Payable and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Accounts Payable vs Net Receivables

Accounts Payable vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Legend Biotech Corp Accounts Payable account and Net Receivables. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Legend Biotech's Accounts Payable and Net Receivables is -0.55. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Legend Biotech Corp, assuming nothing else is changed. The correlation between historical values of Legend Biotech's Accounts Payable and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Legend Biotech Corp are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Accounts Payable i.e., Legend Biotech's Accounts Payable and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Legend Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Legend Biotech Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Receivables

Most indicators from Legend Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Legend Biotech Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

As of the 29th of November 2024, Selling General Administrative is likely to grow to about 112.1 M, while Tax Provision is likely to drop about 268.9 K.

Legend Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets
Total Assets		0.88	0.82	0.86	0.88	-0.6	0.91	0.94	0.25	-0.92	-0.93	0.78	0.91	0.89	0.76	0.27	0.93	-0.57	0.74	0.78	0.87	0.81	0.66	0.9	0.89	1.0
Short Long Term Debt Total	0.88		0.73	0.76	0.97	-0.83	0.97	0.8	0.06	-0.9	-0.96	0.81	0.95	0.94	0.93	0.21	0.95	-0.49	0.81	0.59	0.74	0.96	0.68	0.97	0.77	0.88
Other Current Liab	0.82	0.73		0.99	0.67	-0.34	0.78	0.89	0.14	-0.77	-0.77	0.76	0.76	0.77	0.48	0.57	0.83	-0.84	0.43	0.84	0.85	0.57	0.82	0.72	0.95	0.81
Total Current Liabilities	0.86	0.76	0.99		0.72	-0.34	0.81	0.93	0.23	-0.83	-0.82	0.76	0.81	0.83	0.53	0.51	0.88	-0.86	0.46	0.89	0.91	0.63	0.79	0.77	0.98	0.85
Total Stockholder Equity	0.88	0.97	0.67	0.72		-0.78	0.98	0.8	0.22	-0.95	-0.98	0.69	0.98	0.96	0.95	0.1	0.96	-0.45	0.76	0.59	0.76	0.97	0.55	0.99	0.76	0.88
Other Liab	-0.6	-0.83	-0.34	-0.34	-0.78		-0.76	-0.4	0.36	0.57	0.69	-0.71	-0.66	-0.64	-0.85	-0.1	-0.64	-0.01	-0.82	-0.1	-0.27	-0.82	-0.52	-0.73	-0.32	-0.61
Net Tangible Assets	0.91	0.97	0.78	0.81	0.98	-0.76		0.85	0.15	-0.95	-0.98	0.76	0.97	0.95	0.89	0.2	0.98	-0.52	0.75	0.63	0.78	0.92	0.67	0.98	0.81	0.92
Property Plant And Equipment Net	0.94	0.8	0.89	0.93	0.8	-0.4	0.85		0.37	-0.91	-0.9	0.73	0.88	0.88	0.65	0.26	0.92	-0.79	0.61	0.91	0.95	0.72	0.71	0.85	0.96	0.93
Current Deferred Revenue	0.25	0.06	0.14	0.23	0.22	0.36	0.15	0.37		-0.43	-0.29	-0.32	0.33	0.32	0.14	-0.38	0.29	-0.34	-0.07	0.45	0.56	0.16	-0.35	0.26	0.39	0.24
Net Debt	-0.92	-0.9	-0.77	-0.83	-0.95	0.57	-0.95	-0.91	-0.43		0.98	-0.63	-0.99	-0.98	-0.86	-0.15	-0.98	0.63	-0.63	-0.77	-0.9	-0.9	-0.53	-0.97	-0.88	-0.91
Retained Earnings	-0.93	-0.96	-0.77	-0.82	-0.98	0.69	-0.98	-0.9	-0.29	0.98		-0.72	-0.99	-0.98	-0.9	-0.12	-0.99	0.58	-0.77	-0.71	-0.86	-0.93	-0.62	-0.99	-0.86	-0.93
Accounts Payable	0.78	0.81	0.76	0.76	0.69	-0.71	0.76	0.73	-0.32	-0.63	-0.72		0.69	0.72	0.64	0.56	0.74	-0.55	0.69	0.62	0.59	0.7	0.92	0.7	0.7	0.77
Cash	0.91	0.95	0.76	0.81	0.98	-0.66	0.97	0.88	0.33	-0.99	-0.99	0.69		0.99	0.9	0.16	0.99	-0.6	0.68	0.72	0.86	0.94	0.58	0.99	0.86	0.9
Non Current Assets Total	0.89	0.94	0.77	0.83	0.96	-0.64	0.95	0.88	0.32	-0.98	-0.98	0.72	0.99		0.9	0.23	0.98	-0.65	0.65	0.77	0.88	0.94	0.6	0.97	0.87	0.88
Non Currrent Assets Other	0.76	0.93	0.48	0.53	0.95	-0.85	0.89	0.65	0.14	-0.86	-0.9	0.64	0.9	0.9		0.02	0.86	-0.3	0.76	0.45	0.62	0.99	0.43	0.93	0.59	0.75
Other Assets	0.27	0.21	0.57	0.51	0.1	-0.1	0.2	0.26	-0.38	-0.15	-0.12	0.56	0.16	0.23	0.02		0.22	-0.45	-0.16	0.41	0.24	0.1	0.58	0.1	0.4	0.25
Cash And Short Term Investments	0.93	0.95	0.83	0.88	0.96	-0.64	0.98	0.92	0.29	-0.98	-0.99	0.74	0.99	0.98	0.86	0.22		-0.66	0.69	0.76	0.89	0.91	0.66	0.98	0.9	0.92
Net Receivables	-0.57	-0.49	-0.84	-0.86	-0.45	-0.01	-0.52	-0.79	-0.34	0.63	0.58	-0.55	-0.6	-0.65	-0.3	-0.45	-0.66		-0.14	-0.91	-0.81	-0.41	-0.67	-0.53	-0.86	-0.54
Common Stock Shares Outstanding	0.74	0.81	0.43	0.46	0.76	-0.82	0.75	0.61	-0.07	-0.63	-0.77	0.69	0.68	0.65	0.76	-0.16	0.69	-0.14		0.31	0.49	0.75	0.53	0.76	0.49	0.76
Long Term Debt Total	0.78	0.59	0.84	0.89	0.59	-0.1	0.63	0.91	0.45	-0.77	-0.71	0.62	0.72	0.77	0.45	0.41	0.76	-0.91	0.31		0.93	0.55	0.61	0.65	0.93	0.75
Non Current Liabilities Total	0.87	0.74	0.85	0.91	0.76	-0.27	0.78	0.95	0.56	-0.9	-0.86	0.59	0.86	0.88	0.62	0.24	0.89	-0.81	0.49	0.93		0.7	0.53	0.81	0.97	0.86
Inventory	0.81	0.96	0.57	0.63	0.97	-0.82	0.92	0.72	0.16	-0.9	-0.93	0.7	0.94	0.94	0.99	0.1	0.91	-0.41	0.75	0.55	0.7		0.51	0.95	0.68	0.8
Other Current Assets	0.66	0.68	0.82	0.79	0.55	-0.52	0.67	0.71	-0.35	-0.53	-0.62	0.92	0.58	0.6	0.43	0.58	0.66	-0.67	0.53	0.61	0.53	0.51		0.59	0.69	0.65
Other Stockholder Equity	0.9	0.97	0.72	0.77	0.99	-0.73	0.98	0.85	0.26	-0.97	-0.99	0.7	0.99	0.97	0.93	0.1	0.98	-0.53	0.76	0.65	0.81	0.95	0.59		0.81	0.9
Total Liab	0.89	0.77	0.95	0.98	0.76	-0.32	0.81	0.96	0.39	-0.88	-0.86	0.7	0.86	0.87	0.59	0.4	0.9	-0.86	0.49	0.93	0.97	0.68	0.69	0.81		0.88
Total Current Assets	1.0	0.88	0.81	0.85	0.88	-0.61	0.92	0.93	0.24	-0.91	-0.93	0.77	0.9	0.88	0.75	0.25	0.92	-0.54	0.76	0.75	0.86	0.8	0.65	0.9	0.88

Click cells to compare fundamentals

Legend Biotech Account Relationship Matchups

Legend Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	287.7M	721.0M	1.1B	1.3B	1.8B	938.8M
Short Long Term Debt Total	6.1M	3.4M	123.0M	284.5M	328.7M	345.1M
Other Current Liab	70.9M	100.1M	220.7M	248.0M	132.9M	141.6M
Total Current Liabilities	127.8M	161.2M	280.3M	297.8M	216.4M	203.5M
Total Stockholder Equity	(122.9M)	280.3M	471.2M	744.3M	1.3B	1.3B
Other Liab	277.8M	277.7M	244.8M	7.9M	7.1M	6.7M
Net Tangible Assets	(123.4M)	277.4M	466.5M	740.9M	852.0M	894.6M
Property Plant And Equipment Net	75.5M	121.3M	155.1M	161.7M	189.7M	116.2M
Current Deferred Revenue	46.3M	55.3M	60.9M	451K	53.0M	45.0M
Net Debt	(77.3M)	(452.3M)	(566.0M)	(501.5M)	(949.0M)	(901.6M)
Retained Earnings	(127.3M)	(430.8M)	(817.0M)	(966.5M)	(1.5B)	(1.4B)
Accounts Payable	9.6M	4.9M	7.0M	32.9M	20.2M	13.6M
Cash	83.4M	455.7M	688.9M	786.0M	1.3B	1.3B
Non Current Assets Total	80.6M	128.1M	169.6M	231.8M	350.8M	368.4M
Non Currrent Assets Other	665K	4.0M	5.1M	66.8M	152.4M	160.0M
Other Assets	70.2M	665K	4.2M	7.3M	67.7M	0.95
Cash And Short Term Investments	158.9M	505.7M	882.4M	1.0B	1.3B	1.4B
Net Receivables	35.8M	75.6M	50.5M	45.5M	157.1M	80.2M
Liabilities And Stockholders Equity	287.7M	721.0M	1.1B	1.3B	1.8B	938.8M
Non Current Liabilities Total	282.8M	279.6M	366.9M	288.9M	380.8M	319.7M
Inventory	1.2M	1.8M	1.7M	10.4M	19.4M	20.4M
Other Current Assets	11.3M	10.8M	15.2M	62.8M	12.6M	17.9M
Other Stockholder Equity	3.9M	708.3M	1.3B	1.7B	2.6B	2.8B
Total Liab	410.6M	440.8M	647.2M	586.7M	597.2M	523.2M
Total Current Assets	207.1M	592.9M	948.8M	1.1B	1.5B	770.5M
Accumulated Other Comprehensive Income	(122.9M)	280.2M	471.2M	744.3M	98.9M	94.0M
Short Term Debt	1.0M	1.5M	911K	7.1M	3.2M	2.2M
Intangible Assets	5.1M	7.7M	4.7M	3.4M	4.1M	3.9M
Property Plant Equipment	79.4M	121.1M	152.9M	160.8M	184.9M	100.7M
Short Term Investments	75.6M	50M	193.5M	239.6M	31.0M	29.5M
Capital Lease Obligations	6.1M	3.4M	2.5M	23.6M	47.3M	49.7M
Net Invested Capital	(122.9M)	280.3M	591.7M	1.0B	1.5B	1.6B
Property Plant And Equipment Gross	74.8M	116.5M	155.1M	161.7M	224.7M	140.2M
Net Working Capital	79.3M	431.7M	668.5M	801.3M	1.3B	1.3B

Pair Trading with Legend Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Legend Stock

0.67

ELAN

Elanco Animal Health Potential Growth

Pair Corr

Moving against Legend Stock

0.84	GILD	Gilead Sciences	Pair Corr
0.78	EWTX	Edgewise Therapeutics	Pair Corr
0.78	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.76	BHC	Bausch Health Companies	Pair Corr
0.68	ESPR	Esperion Therapeutics	Pair Corr

The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.

The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:

How To Invest In Legend

Details

Is Legend Stock a good investment?

Details

What is Legend Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.92)

Revenue Per Share

2.851

Quarterly Revenue Growth

0.669

Return On Assets

(0.12)

Return On Equity

(0.28)

The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Legend Accounts Payable vs Net Receivables Analysis

Accounts Payable vs Net Receivables

Accounts Payable vs Net Receivables Correlation Analysis

Correlation Coefficient

Accounts Payable

Net Receivables

Legend Biotech fundamental ratios Correlations

Legend Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Legend Biotech fundamental ratios Accounts

Pair Trading with Legend Biotech

Moving together with Legend Stock

Moving against Legend Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.99	Cash
Cash And Short Term Investments	+ 0.99	Cash
Other Stockholder Equity	+ 0.99	Cash

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Retained Earnings
Cash	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Non Current Assets Total	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Net Debt